

Tecentriq® (atezolizumab) – New indication approval

- On July 31, 2020, <u>Roche announced</u> the <u>FDA approval</u> of <u>Tecentriq (atezolizumab)</u>, in combination with <u>Cotellic[®] (cobimetinib)</u> and <u>Zelboraf[®] (vemurafenib)</u> for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
- Tecentriq is also indicated for the treatment of urothelial carcinoma, non-small cell lung cancer, triple negative breast cancer, small cell lung cancer, and hepatorcellular carcinoma.
- The approval of the new indication for Tecentriq was based on a double-blind study of 514 patients
 with previously untreated unresectable or metastatic BRAF V600 mutation-positive melanoma.
 Patients were randomized to Tecentriq plus Cotellic and Zelboraf or placebo plus Cotellic and
 Zelboraf until disease progression or unacceptable toxicity. The primary efficacy outcome was
 progression-free survival (PFS).
 - The median PFS was 15.1 months for the Tecentriq plus Cotellic and Zelboraf group vs. 10.6 months for the Cotellic and Zelboraf group (hazard ratio: 0.78; 95% CI: 0.63, 0.97; p = 0.0429).
 - In addition, the overall response rate was seen in 66% (95% CI: 60, 72) of the Tecentriq plus Cotellic and Zelboraf group vs. 65% (95% CI: 59, 71) of the Cotellic and Zelboraf group.
 - The median duration of response was 20.4 months (95% CI: 15.1, NE) for the Tecentriq plus Cotellic and Zelboraf group vs. 12.5 months (95% CI: 10.7, 16.6) for the Cotellic and Zelboraf group.
- The most common adverse reactions (≥ 20%) with Tecentriq in combination with Cotellic and Zelboraf were rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, and photosensitivity reaction.
- The recommended dose of Tecentriq is 840 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity, when administered with Cotellic 60 mg orally once daily (21 days on and 7 days off) and Zelboraf 720 mg orally twice daily.
 - Prior to initiating Tecentriq, patients should receive a 28 day treatment cycle of Cotellic 60 mg orally once daily (21 days on and 7 days off) and Zelboraf 960 mg orally twice daily from days 1-21 and Zelboraf 720 mg orally twice daily from days 22-28.
 - Select patients with unresectable or metastatic melanoma for treatment with Tecentriq in combination with Cotellic and Zelboraf after confirming the presence of a BRAF V600 mutation. Information on FDA-approved tests for the detection of BRAF V600E and V600K mutations in melanoma is available at http://www.fda.gov/CompanionDiagnostics.
 - Consult Cotellic and Zelboraf's drug labels for further dosing information.
 - Consult Tecentrig's drug label for dosing recommendations for all its other indications.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.